Search

Your search keyword '"Bergenstal, R"' showing total 259 results

Search Constraints

Start Over You searched for: Author "Bergenstal, R" Remove constraint Author: "Bergenstal, R"
259 results on '"Bergenstal, R"'

Search Results

1. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

2. Glycemic Control and Urinary Tract Infections in Women with Type 1 Diabetes: Results from the DCCT/EDIC

3. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort

4. Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort

9. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

13. Effets de l’insuline Efsitora alfa (Efsitora) sur la fréquence et la sévérité de des hypoglycémies dans des conditions de risque hypoglycémique accru par rapport à l’insuline glargine chez les patients vivant avec un diabète de type 2 (DT2)

20. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

24. Liraglutide and Renal Outcomes in Type 2 Diabetes

25. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

26. High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial

27. Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

28. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial

29. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

31. Oxidative Stress and Cardiovascular Risk in Type 1 Diabetes Mellitus: Insights From the DCCT/EDIC Study

32. Significance of epicardial and intrathoracic adipose tissue volume among type 1 diabetes patients in the DCCT/EDIC: A pilot study

33. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME (R) trial

34. Schnell wirksames Insulin aspart (Faster aspart) vs. Insulin aspart zur Mahlzeit im Rahmen einer Basal-Bolus-Behandlung verbesserte die Blutzuckereinstellung bei T1D: die doppelblinde onset® 1-Studie

35. LEADER 2:baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

36. Liraglutide and cardiovascular outcomes in type 2 diabetes

37. L’insuline asparte ultra-rapide vs insuline asparte en prandiale améliore le contrôle glycémique chez les patients DT1 : étude onset® 1

40. Alogliptin after acute coronary syndrome in patients with type 2 diabetes

41. Differences in the Management of Type 1 Diabetes Among Adults Under Excellent Control Compared With Those Under Poor Control in the T1D Exchange Clinic Registry

42. P313 Première année de suivi des patients diabétiques de type 2 traités par l’insuline glargine 300 U/ml vs l’insuline glargine 100 U/ml, associées aux antidiabétiques oraux: moins de prise de poids et d’hypoglycémies nocturnes (étude DITION 2)

47. Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Catalog

Books, media, physical & digital resources